Search results
Results from the WOW.Com Content Network
Fluphenazine, sold under the brand name Prolixin among others, is a high-potency typical antipsychotic medication. [2] It is used in the treatment of chronic psychoses such as schizophrenia , [ 2 ] [ 3 ] and appears to be about equal in effectiveness to low-potency antipsychotics like chlorpromazine . [ 4 ]
Note: All by intramuscular injection. Footnotes: a = Microcrystalline or nanocrystalline aqueous suspension . b = Low- viscosity vegetable oil (specifically fractionated coconut oil with medium-chain triglycerides ).
Another traditional antipsychotic used in treating Tourette's is fluphenazine (brand name Prolixin), although the evidence supporting its use is less than that of haloperidol and pimozide. [4] The classes of medication with proven efficacy in treating tics—typical and atypical neuroleptics—can have long-term and short-term adverse effects. [4]
The first long-acting (depot) injections were antipsychotics fluphenazine and haloperidol. [2] The concept of a depot injection arose before 1950, and originally was used to describe antibiotic injections that lasted longer to allow for less frequent administration. [4]
They may be administered orally or, in some cases, through long-acting (depot) injections administered in the dorsgluteal, ventrogluteal or deltoid muscle. Short-acting parenteral formulations also exist, which are generally reserved for emergencies or when oral administration is otherwise impossible.
Together, these modifications prevent the active medications from being released immediately upon injection, attaining a slow release of the active medications (note, though, that the fluphenazine decanoate product is unique for reaching peak fluphenazine blood levels within 24 hours after administration [19]). [18]
The last image we have of Patrick Cagey is of his first moments as a free man. He has just walked out of a 30-day drug treatment center in Georgetown, Kentucky, dressed in gym clothes and carrying a Nike duffel bag.
The approval of aripiprazole lauroxil from the Food and Drug Administration in 2015 was solely for the treatment of schizophrenia in adults. The ability to supplement aripiprazole lauroxil with oral supplements of aripiprazole allows for dosing flexibility, which is important for the treatment of schizophrenia, as symptoms and intensity of the disease vary greatly from patient to patient.